Biosynex SA

Paris Stock Exchange ALBIO.PA

Biosynex SA Gross Profit for the year ending December 31, 2023: USD 54.23 M

Biosynex SA Gross Profit is USD 54.23 M for the year ending December 31, 2023, a -21.44% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Biosynex SA Gross Profit for the year ending December 31, 2022 was USD 69.03 M, a -66.78% change year over year.
  • Biosynex SA Gross Profit for the year ending December 31, 2021 was USD 207.81 M, a 253.68% change year over year.
  • Biosynex SA Gross Profit for the year ending December 31, 2020 was USD 58.76 M, a 2,717.58% change year over year.
  • Biosynex SA Gross Profit for the year ending December 31, 2019 was USD 2.09 M, a -79.20% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
Paris Stock Exchange: ALBIO.PA

Biosynex SA

CEO Mr. Larry Abensur
IPO Date March 28, 2011
Location France
Headquarters 22 Boulevard Sébastien Brant
Employees 515
Sector Health Care
Industries
Description

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.

Similar companies

ALERS.PA

Eurobio Scientific Société anonyme

USD 26.07

0.60%

StockViz Staff

January 15, 2025

Any question? Send us an email